Latest Schedule 13G passive stakes

Invesco Ltd. has disclosed beneficial ownership of 6.2% of Charles River Laboratories International Inc.'s common stock as of June 30, 2026.

Invesco Ltd. has disclosed beneficial ownership of 6.2% of Charles River Laboratories International Inc.'s common stock as of June 30, 2026.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amendment to their Schedule 13G, reporting zero beneficial ownership of Class A Ordinary Shares of Fortress Value Acquisition Corp. V.

Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amendment to their Schedule 13G, reporting zero beneficial ownership of Class A Ordinary Shares of Fortress Value Acquisition Corp. V.

Laurence W. Lytton has reported beneficial ownership of 100,521 shares, representing 6.8% of DNA X, Inc.'s common stock, as of June 30, 2026.

Invesco Ltd. has reported beneficial ownership of 5.4% of Canaan Inc.'s American Depository Receipts, totaling over 606 million shares.

Invesco Ltd. has reported beneficial ownership of 5.4% of Canaan Inc.'s American Depository Receipts, totaling over 606 million shares.

Invesco Ltd. has disclosed beneficial ownership of 5.5% of Atmus Filtration Technologies Inc.'s common stock as of June 30, 2026.

Invesco Ltd. has disclosed beneficial ownership of 5.5% of Atmus Filtration Technologies Inc.'s common stock as of June 30, 2026.

Invesco Ltd. has disclosed beneficial ownership of 1,650,643 shares, representing 7.4% of ArcBest Corp's common stock, as of June 30, 2026.

Invesco Ltd. has disclosed beneficial ownership of 1,650,643 shares, representing 7.4% of ArcBest Corp's common stock, as of June 30, 2026.

Laurence W. Lytton has reported beneficial ownership of 5,592,972 shares, representing 5.2% of Codexis, Inc. common stock, as of June 30, 2026.

Laurence W. Lytton and the Lytton-Kambara Foundation have jointly filed a Schedule 13G, reporting a combined beneficial ownership of approximately 9.9% in Scientific Industries Inc., indicating a substantial passive investment.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.7% of Esperion Therapeutics, Inc. common stock as of June 30, 2026.

Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 6.7% of Esperion Therapeutics, Inc. common stock as of June 30, 2026.

Laurence W. Lytton has reported a beneficial ownership of 9.6% in MDxHealth SA's ordinary shares.

Invesco Ltd. has disclosed a beneficial ownership of 13,678,393 shares, representing 7.3% of the common stock of Allegro MicroSystems Inc.

Invesco Ltd. has disclosed a beneficial ownership of 13,678,393 shares, representing 7.3% of the common stock of Allegro MicroSystems Inc.

Brandes Investment Partners, L.P. has updated its Schedule 13G filing to reflect its beneficial ownership of Globant S.A. common shares.

Laurence W. Lytton has filed a Schedule 13G, reporting beneficial ownership of 959,856 shares, representing 7.5% of Ideal Power Inc.'s common stock.

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting beneficial ownership of Chart Industries, Inc. common stock.

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC have filed an amended Schedule 13G, reporting beneficial ownership of Chart Industries, Inc. common stock.

Enstar Group Limited and affiliated entities report a 5.6% beneficial ownership stake in James River Group Holdings, Ltd. common shares.

Enstar Group Limited and affiliated entities report a 5.6% beneficial ownership stake in James River Group Holdings, Ltd. common shares.

Enstar Group Limited and its affiliates have disclosed a significant beneficial ownership stake of 16.6% in Eagle Point Income Company, Inc.

Enstar Group Limited and its affiliates have disclosed a significant beneficial ownership stake of 16.6% in Eagle Point Income Company, Inc.

Invesco Ltd. has disclosed beneficial ownership of 10,365,640 shares, representing 5.0% of the common stock of Alignment Healthcare Inc., as of June 30, 2026.

Invesco Ltd. has disclosed beneficial ownership of 10,365,640 shares, representing 5.0% of the common stock of Alignment Healthcare Inc., as of June 30, 2026.

Laurence W. Lytton has reported beneficial ownership of 4,238,628 shares, representing 4.9% of Rein Therapeutics, Inc. common stock, as of June 30, 2026.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed a Schedule 13G, reporting beneficial ownership of 3.5% of Bold Eagle Acquisition Corp.'s Class A ordinary shares as of June 30, 2026.